Behera Geeta, Gokhale Tanmay, Babu Krishna R
Ophthalmology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND.
Cureus. 2021 Oct 27;13(10):e19084. doi: 10.7759/cureus.19084. eCollection 2021 Oct.
Here, we report a case of acute endothelial graft rejection following coronavirus disease 2019 (COVID-19). A 57-year-old woman who underwent therapeutic penetrating keratoplasty for a perforated infectious corneal ulcer in her right eye developed severe acute respiratory syndrome coronavirus 2 infection, which required intensive care and treatment with steroids. Acute endothelial graft rejection was seen at three weeks postoperatively and managed with high-dose corticosteroids. Despite standard therapy, secondary graft failure was observed. Immune dysregulation associated with COVID-19 may be a significant cause of acute endothelial graft rejection among keratoplasty patients with COVID-19.
在此,我们报告一例2019冠状病毒病(COVID-19)后发生的急性内皮移植排斥反应病例。一名57岁女性因右眼穿孔性感染性角膜溃疡接受了治疗性穿透性角膜移植术,随后感染了严重急性呼吸综合征冠状病毒2,需要重症监护并使用类固醇进行治疗。术后三周出现急性内皮移植排斥反应,采用大剂量皮质类固醇进行处理。尽管进行了标准治疗,但仍观察到继发性移植失败。与COVID-19相关的免疫失调可能是COVID-19角膜移植患者急性内皮移植排斥反应的一个重要原因。